Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer

NCT03088930 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT03088930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03088930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2017
Completion date
January 13, 2021
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, nonsmall cell